Clinical Trial

β-alanine in the Treatment of Advanced Hepatocellular Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a prospective, randomized controlled study on nutritional support and metabolic regulation. It assesses the safety, compliance, and improvement of metabolic/physical-related indicators when using β-alanine within the specified dose range as dietary supplementation, in addition to the standard first-line treatment. The anti-tumor efficacy (ORR, PFS, OS) is the exploratory endpoint.
Trial Details
NCT Number NCT07317414
Lead Sponsor Peking Union Medical College Hospital
Conditions Hepatocellular Carcinoma
Enrollment 158 participants
Start Date 2025-12-24
Primary Completion 2028-12-05 (estimated)
Study Completion 2030-12-05 (estimated)
Updated on ClinicalTrials.gov 2026-01-05